ProPhase Labs Announces Significant Progress in BE-Smart Esophageal Cancer Test Development USPTO grants additional broad patents for BE-SMART
February 20, 2024 08:00 ET
|
ProPhase Labs, Inc.
Garden City, NY, Feb. 20, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics and diagnostics company, today announced important developments in the...
ProPhase poised to ramp up growth at Pharmaloz and Nebula Genomics in 2024
January 04, 2024 08:00 ET
|
ProPhase Labs, Inc.
Company also plans to commercialize its BE-Smart Esophageal Cancer Test in 2024Company announces the hiring of long-time industry veteran Jed Latkin as COO to help build and manage this growth Garden...
ProPhase Labs Announces Financial Results for the Three Months Ended June 30, 2023
August 10, 2023 08:00 ET
|
ProPhase Labs, Inc.
Company believes that the combined value of its five operating units exceeds its current market capitalization and that each unit has significant growth potential. Company highlights...
ProPhase Labs Closes Acquisition of BE-Smart Esophageal Pre-Cancer Diagnostic Screening Test
January 05, 2023 08:00 ET
|
ProPhase Labs, Inc.
GARDEN CITY, NY, Jan. 05, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a growth oriented and diversified diagnostics, genomics and biotech company, today announced it...